CELL INTELLIGENCE · 肿瘤细胞治疗研究

PDPN 与 GD2 双靶向增强 CAR-T 细胞对胶质母细胞瘤的疗效并促进持久肿瘤控制

Dual targeting of PDPN and GD2 enhances CAR T cell efficacy against glioblastoma and promotes durable tumor control.

胶质母细胞瘤的代谢与翻译后脆弱性：二硫死亡、糖基化及对 CAR-T 治疗的启示

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.

靶向 PDPN 与 GD2 的新型 CAR-T 细胞组合以克服胶质母细胞瘤异质性

Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity.

这种新型 PDPN/GD2 CAR-T 细胞混合物在晚期临床前胶质母细胞瘤模型中显示出强效疗效，提示其具有治疗异质性胶质母细胞瘤和解决单抗原 CAR-T 细胞疗法相关局限性的潜力。

胶质瘤中的 NK 细胞功能障碍：从免疫逃逸到免疫治疗

Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.

靶向癌症干细胞的 CAR 免疫疗法：生物学、证据和未来方向

Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions.

工程化声遗传 EchoBack-CAR-T 细胞

Engineering sonogenetic EchoBack-CAR T cells.

体外评估 GD2 CAR-T 细胞对胶质母细胞瘤的抗肿瘤活性

Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma

这是一项分期未标注的注册临床试验，评估细胞治疗用于胶质母细胞瘤的安全性、可行性及初步疗效。当前状态：尚未开始招募。计划入组 18 例。试验地点：欧洲 · 旺德夫尔莱南锡（共 1 个中心）。登记号：NCT06764537。

CAR-T 细胞治疗恶性胶质瘤的临床开发进展

Clinical progress in the development of CAR T cells to treat malignant glioma.

在研 CAR-T 细胞疗法的快速演进预示着胶质瘤治疗未来的巨大潜力。

热响应支架作为 3D 合成基质用于抗胶质母细胞瘤球体 CAR-T 效力检测的体外评估

In Vitro Assessment of Thermo-Responsive Scaffold as a 3D Synthetic Matrix for CAR-T Potency Testing Against Glioblastoma Spheroids.

CAR-T 细胞治疗神经系统肿瘤

CAR-T Cells in the Treatment of Nervous System Tumors.